Children’s development set back years by Covid lockdowns, study reveals
Peer-Reviewed Publication
Updates every hour. Last Updated: 4-Mar-2026 09:15 ET (4-Mar-2026 14:15 GMT/UTC)
New research reveals that Covid lockdowns set children's development back by years. The study shows how the pandemic hampered children’s ability to regulate their behaviour, stay focused and adapt to new situations. The greatest impact was seen among pupils who were in reception year (ages four-five) when the first lockdowns began - a crucial stage when youngsters normally learn to socialise, follow routines and navigate the busy world of the classroom.
The team say that children may still be feeling the effects years later.
A UC San Diego study shows that taking a mushroom-derived supplement during COVID-19 vaccination was safe, eased short-term side effects, and supported longer-lasting immune responses, particularly for people receiving their first vaccine.
Scientists have identified molecular and structural changes in taste buds that may explain why a small subset of people experience long-term taste loss after COVID-19 infection.
Researchers at the NUS Yong Loo Lin School of Medicine and Monash University have developed a vaccine booster candidate administered via the nasal route, which confers strong immunity in the respiratory tract. The study offers a promising strategy to enhance immunity and inform future booster approaches.
The COVID-19 pandemic was a major health crisis that challenged citizens’ information management routines. Epistemic ideals guided how people scanned and filtered information, engaged with it and adapted their behaviour accordingly. Conducted in Finland, a recent study found that four distinctive profiles characterise citizens’ engagement with information.
A new review from the Antiviral Gene Therapy Research Unit (AGTRU) at the University of the Witwatersrand highlights how viral mimic systems and related technologies could accelerate the development of vaccines and antiviral therapies, particularly in low-resource settings. Published in the journal Infection, the review describes safe, virus-like platforms that replicate key features of dangerous pathogens without the ability to cause disease.
Conventional antiviral research often requires biosafety level-3 laboratories, which are expensive, tightly regulated, and scarce. Viral mimic systems overcome this bottleneck by enabling scientists to study infection, screen drug candidates, and compare immune responses in standard biosafety level-2 facilities. This allows promising therapies to move more quickly from laboratory testing to clinical development.
The review focuses on technologies such as pseudo-typed viruses and virus-like particles that reproduce the early stages of infection. More advanced models incorporate all four structural proteins of SARS-CoV-2, offering a more realistic picture of viral behaviour and helping researchers design broader, more durable vaccines that remain effective against emerging variants.